In a more comparable study, Konsti et al (2011) reported that automated assessment of Ki-67 proliferative activity had prognostic value in 1334 breast cancer patients, but did not examine the survival relationships in the subgroup of patients who received Tamoxifen. The gene discussed is MKI67; the disease is breast carcinoma.